Service hotline:
NEWS CENTER
HEBEI ZHENGXING GLASS CO., LTD
State Food and Drug Administration conditionally approved the registration application of novel Coronavirus protein vaccine (CHO cells) of Anhui Zhifei Longkoma Biopharmaceutical Co., LTD
Time：
2022-06-29 09:16
On 1 March, the State Medical Products Administration conditionally approved the application for marketing registration of the recombinant Novel Coronavirus protein vaccine (CHO cells) from Anhui Zhifei Longkoma Biopharmaceutical Co., LTD. The vaccine is the first domestically approved recombinant Novel Coronavirus protein vaccine for the prevention of disease caused by Novel Coronavirus infection (COVID-19).
According to the relevant provisions of the Vaccine Administration Law and the Drug Administration Law, the SFDA conducted emergency review and approval in accordance with the special drug approval procedures, and approved the application for marketing registration of the vaccine with conditions. The SFDA asked the holder of marketing authorization for the vaccine to continue to carry out relevant research work, complete the conditional requirements, and submit follow-up research results in a timely manner.
Relevant information
Service hotline
Add: Shijiazhuang City Luancheng District sinus crone town Wang Village
Contact person: Manager Ma
Tel：+86-311-85507898
Tel：+86-13073179975
E-mail：msm@hbzxbl.com
Focus on WeChat
Hebei Zhengxing Glass Co., LTD Powered by www.300.cn | SEO | NEWS